Unlock the Editor’s Digest free of charge
Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly e-newsletter.
Eli Lilly raised its income forecast for 2024, sending its shares hovering, because the world’s greatest drugmaker by market worth continues to profit from bumper gross sales of its blockbuster diabetes and weight reduction medication.
The Indianapolis-based firm on Thursday elevated its full-year gross sales steering by $3bn to between $45.4bn and $46.6bn, citing the “sturdy efficiency of Mounjaro and Zepbound”, its new class of diabetes and weight reduction medicines referred to as GLP-1s.
Income within the second quarter elevated 36 per cent yr on yr to $11bn, whereas internet earnings rose 68 per cent to $2.97bn, beating analysts’ expectations on each counts.
The gross sales boosts recommend that Eli Lilly has an edge over rival weight reduction drugmaker Novo Nordisk within the race to spice up manufacturing capability to fulfill demand for a market that Goldman Sachs analysts estimate may very well be value $130bn in peak annual gross sales. The Danish drugmaker’s gross sales got here in beneath analyst expectations on Wednesday due to manufacturing challenges.
Eli Lilly chief govt David Ricks mentioned the higher than anticipated gross sales in its most up-to-date quarter had been pushed by the GLP-1 medicines because the drugmaker “superior our manufacturing growth agenda” to fulfill the large demand for the medicines. Elevated pricing energy for Mounjaro additionally boosted revenues, the corporate mentioned.
Gross sales of recent merchandise, which embody the GLP-1 medicines, rose $3.5bn to $4.5bn. Gross sales of diabetes drug Mounjaro totalled $3.1bn within the second quarter, whereas revenues from anti-obesity remedy Zepbound reached $1.2bn.
Evan Seigerman, a pharma trade analyst at BMO Capital Markets, mentioned the quarterly earnings advised that Eli Lilly was besting Novo Nordisk and “pulling forward within the metabolic duopoly”.
Eli Lilly’s shares jumped greater than 9 per cent shortly after Wall Road’s opening bell on Thursday, taking the pharmaceutical group’s market capitalisation again above $800bn for the primary time in a fortnight. The corporate’s share worth has slid in latest weeks as a broader market rotation had traders flocking to cheaper pharmaceutical shares and undervalued weight reduction drugmakers comparable to Roche.
Final week, 4 completely different doses of Mounjaro and Zepbound had been faraway from a US Meals and Drug Administration database monitoring drug shortages in an indication that provide constraints have eased. The medicines had been listed as “obtainable”, however nonetheless stay on the company’s shortages listing.
Rival weight reduction drugmaker Novo Nordisk, which manufactures diabetes drug Ozempic and its anti-obesity offshoot Wegovy, on Wednesday reported second-quarter gross sales that had been barely beneath analysts’ expectations. That provoked considerations from traders that it was being outmanoeuvred by Eli Lilly within the race to spice up manufacturing capability, leading to Novo’s shares closing 6.7 per cent decrease on the day.
BMO Capital Markets’ Seigerman mentioned in a analysis observe that Eli Lilly’s outcomes had been “spectacular” and “replicate enhancing provide dynamics for the corporate’s [GLP-1] portfolio and better realised costs for Mounjaro within the US.”
